Role of HIF-PHD inhibitor in improving adherence and safety in the treatment of anemia in chronic kidney disease

BABITT JL, LIN HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634. https://doi.org/10.1681/ASN.2011111078

PALMER SC, SAGLIMBENE V, MAVRIDIS D, SALANTI G, CRAIG JC, TONELLI M et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014; 2014: CD010590. https://doi.org/10.1002/14651858.CD010590.pub2

THAVARAJAH S, CHOI MJ. The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach. Am J Kidney Dis 2019; 74: 667-674. Available from: https://doi.org/10.1053/j.ajkd.2019.04.022

BESARAB A, BOLTON WK, BROWNE JK, EGRIE JC, NISSENSON AR, OKAMOTO DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. https://doi.org/10.1056/NEJM199808273390903

SINGH AK, SZCZECH L, TANG KL, BARNHART H, SAPP S, WOLFSON M et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. https://doi.org/10.1056/NEJMoa065485

DRÜEKE T, LOCATELLI F, CLYNE N, ECKARDT K-U, MACDOUGALL IC, TSAKIRIS D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2015; 687-696. https://doi.org/10.1056/NEJMoa062276

FOLEY RN, PARFREY PS, MORGAN J, BARRE PE, CAMPBELL P, CARTIER P et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335. https://doi.org/10.1046/j.1523-1755.2000.00289.x

WEBSTER AC, NAGLER EV, MORTON RL, MASSON P. Chronic Kidney Disease. Lancet 2017; 389: 1238-1252. https://doi.org/10.1016/S0140-6736(16)32064-5

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335. http://kdigo.org/home/guidelines/anemia-in-ckd/%5Cnhttp://linkinghub.elsevier.com/retrieve/pii/S2157171615310777

DÍEZ CP, AZNÁREZ HN, ARNAL LML. Adherence to treatment with erythropoiesis stimulating agents. An Sist Sanit Navar 2020; 43: 81-85. https://doi.org/10.23938/ASSN.0858

WAZNY LD, STOJIMIROVIC BB, HEIDENHEIM P, BLAKE PG. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002; 40: 623-628. https://doi.org/10.1053/ajkd.2002.34925

CHEN N, HAO C, PENG X, LIN H, YIN A, HAO L et al. roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019; 381: 1001-1010. https://doi.org/10.1056/NEJMoa1813599

CHEN N, HAO C, LIU B-C, LIN H, WANG C, XING C et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019; 381: 1011-1022. https://doi.org/10.1056/NEJMoa1901713

CHERTOW GM, PERGOLA PE, FARAG YMK, AGARWAL R, ARNOLD S, BAKO G et al. Vadadustat in patients with anemia and non–dialysis-dependent CKD. N Engl J Med 2021; 384: 1589-1600. https://doi.org/10.1056/NEJMoa2035938

ECKARDT K-U, AGARWAL R, ASWAD A, AWAD A, BLOCK GA, BACCI MR et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med 2021; 384: 1601-1612. https://doi.org/10.1056/NEJMoa2025956